Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.61 |
| ▸ | FPR1 | P21462 | 5/20 | 0.45 |
| ▸ | FPR2 | P25090 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22831436 | 1.00 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4FPR1FPR2 | |
| SCHEMBL28464602 | 1.00 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4FPR1FPR2 | |
| SCHEMBL29434443 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL14812210 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL14811014 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL2791362 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL16784599 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL14812149 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL14810578 | 0.85 | SLC6A3 (0.51) | SLC6A3MEN1POLBHTTKMT2A | |
| SCHEMBL20177486 | 0.84 | F2RL1 (0.54) | SLC6A3SLC6A2SLC6A4MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018092916-A1 | NITROGEN-CONTAINING POLYCYCLIC HETEROCYCLIC DERIVATIVE | 宇部興産株式会社 | 2018-05-24 | — | — | WO | disclosed |
| EP-2298730-B1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8791295-B2 | Method of producing purified optically acitve 4-amino-3-(substituted phenyl)butanoic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8293926-B2 | Method of producing optically active 4-amino-3-substituted phenylbutanoic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090137819-A1 | Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137819-A1 | Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid | ALAD, ATP6V1B1, DAO | SLC6A3 979/4885SLC6A2 1200/4885SLC6A4 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.